Global High-density Multiplexed Diagnostic Assays Market - Drivers and Forecasts by Technavio

Technavio has published a new report on the global high-density multiplexed diagnostic assays market from 2017-2021. (Graphic: Business Wire)

LONDON--()--Technavio analysts forecast the global high-density multiplexed diagnostic assays market to grow at a CAGR of more than 15% during the forecast period, according to their latest report.

The research study covers the present scenario and growth prospects of the global high-density multiplexed diagnostic assays market for 2017-2021. The market is segmented based on the product (high-density multiplexed diagnostic assays and very high-density multiplexed diagnostic assays) and end-user (hospitals and clinics and clinical diagnostics laboratories). The market is further segmented into geography, including the Americas, EMEA, and APAC.

The global high-density multiplexed diagnostic assays market is influenced by the growing older population and increased prevalence of chronic diseases and infections such as cancer, tuberculosis, malaria, diabetes, and CVDs. The growing awareness of immunodiagnostics among the people, rapid advances in technology and innovations, and growing product approvals are expected to propel the market growth in the future.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio healthcare and life science research analysts highlight the following three factors that are contributing to the growth of the global high-density multiplexed diagnostic assays market:

  • Increasing equipment rental agreements
  • Increasing prevalence of diseases
  • Increasing use of personalized medicine

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Increasing equipment rental agreements

Most of the instruments such as clinical chemistry analyzers, immunochemistry analyzers, and multiplexed diagnostic equipment used in the IVD market are provided for rental or lease to the end-users. They need to pay for the initial installations and consumables. Leasing the high-cost instruments is an effective and convenient purchasing alternative for the end-users with limited budgets.

Srinivas Sashidhar, a lead in-vitro diagnostics research analyst at Technavio, says, “The government increases the flexibility and provides tax benefits to improve the business of manufacturers. Currently, around 70%-80% businesses lease IVD instruments. The rise in the incidence of infectious diseases such as tuberculosis, bacterial infections, and other lifestyle changes contribute to the global high-density multiplexed diagnostic assays market.

Increasing prevalence of diseases

There has been a rise in the incidence and prevalence of oncology, infectious, and cardiac diseases globally. The prevalence of autoimmune diseases is rising worldwide, contributing to the multiplexed diagnostic assays market. According to the CDC, about 22.7% of adults suffer from arthritis in the US. Due to the rise in the older population, the prevalence of arthritis is expected to increase during the forecast period.

Bio-Plex Pro cell signaling assays by Bio-Rad Laboratories are magnetic bead-based immunoassays. These assays help in the autoimmune disease detection. Rheumatoid arthritis and SLE are studied using multiplex diagnostic assays for the treatment of autoimmune diseases.

Increasing use of personalized medicine

The molecular diagnostics helps in understanding the molecular mechanism of a diseased individual. It plays an essential role in the advent of precision and personalized medicines for patients. The molecular diagnosis serves beneficial in the early detection of disease and appropriate treatment option. Molecular diagnostics helps in the integration of therapeutics for meeting the requirement of personalized medicine.

Canada is one of the promising markets for the development of personalized medicines. The CIHR has collaborated with various institutes to accelerate drug discovery in personalized medicines, mainly in the field of oncology. In Mexico, there are various campaigns organized for the introduction of personalized medicine,” adds Srinivas.

Top vendors:

  • Thermo Fisher Scientific
  • Abbott
  • F. Hoffmann-La Roche

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio analysts forecast the global high-density multiplexed diagnostic assays market to grow at a CAGR of more than 15% through 2021.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com